Good day,
Thank you for subscribing to the Earnings360 newsletter, your daily source for quarterly earnings news and updates.
Each morning edition contains a wrap-up of today's pre-market earnings announcements and yesterday's earnings announcements after the closing bell.
Before we send you your first edition, please take a moment to confirm your subscription below. We will not be able to send your newsletter until you confirm your subscription.
Confirm Your Subscription Here
The Earnings360 Team
For Your Education and Enjoyment Growth Picks: 3 Low-Cost Stocks That Could Double in ValueWritten by Chris Markoch. Published 10/27/2025. 
Key Points - Three undervalued growth stocks trading under $50 could deliver major upside if market conditions strengthen in 2026.
- Equinox Gold, Birkenstock, and Immunocore each carry analyst price targets suggesting 50% to 100% potential gains.
- Rising institutional interest, improving earnings, and biotech innovation make these stocks compelling buy-and-hold opportunities.
Many stocks are objectively overvalued, which makes it harder for investors to find opportunities with the potential to double. Penny stocks (i.e., shares trading below $5) are often cited, but their risk-reward profile typically suits only very risk-tolerant, nimble investors. There are still opportunities. One way to find them is to look at analyst sentiment. Analysts don't always get it right, but they often have access to data and company sources that retail investors do not. Their views are therefore useful to consider when doing due diligence. Wall Street's already moving while most traders are still reacting — powered by data and AI tools the rest of us don't see. That's why we built Fierce Free Alerts: real-time signal notifications that cut through the noise and trigger the moment smart setups start forming. Activate your free real-time trading alerts now With that in mind, here are three stocks currently trading under $50 per share that show significant upside potential. Analysts aren't necessarily forecasting outright doubles for each, but consensus price targets are close enough that they could roughly double if the economy and company fundamentals evolve as expected. Equinox Gold: Gold's Momentum Could Keep Running Equinox Gold Corp. (NYSEAMERICAN: EQX) is a Canadian gold-mining company. As of Oct. 27, 2025, EQX stock is up roughly 100% year-to-date. Analysts give the stock a consensus price target of $26, implying upside of about 149% from current levels. Equinox is a leveraged way for equity investors to play higher gold prices. Some bullish analysts even forecast the spot price of gold could reach $5,000 before the end of 2025, with further upside possible in 2026. Higher spot prices make Equinox's mining operations more profitable. The main risk is that the gold rally could reverse. Institutional investor ownership in EQX is only about 38%, but it has been climbing sharply over the last 12 months and is higher than it was two years ago, which may be a constructive sign. Birkenstock: A Consumer Stock Ready to Rebound It's been a difficult year for consumer discretionary stocks like Birkenstock Group AG (NYSE: BIRK). BIRK is down roughly 25% year-to-date in 2025, but the company may be getting lumped in with a weak retail sector despite solid positioning. Both revenue and earnings are higher year over year, with double-digit revenue growth across segments and channels. Analysts project earnings growth of more than 26% over the next 12 months, which dovetails with a forward price-to-earnings (P/E) ratio near 23x. BIRK also carries relatively high short interest—around 17%—though that level has declined in the past month. That could indicate short sellers are trimming positions and leaves the potential for a short squeeze if the stock rallies sharply. Analysts assign BIRK a consensus price target of $68.38, implying roughly 58% upside. The company reports third-quarter earnings on Dec. 17, and a strong holiday season could boost the stock heading into 2026. Immunocore: Biotech With Breakthrough Potential Immunocore plc (NASDAQ: IMCR) is a biotechnology company developing cancer therapies using T-cell technology. As of August 2025, the company has one drug that completed clinical trials successfully and three candidates in or entering Phase 3 trials. Biotech names are often targeted for their potential to double because a single successful drug approval can dramatically re-rate a company. Immunocore is already generating measurable revenue and may be moving toward profitability. Analysts give IMCR a consensus price target of $61. More bullish, HC Wainwright reiterated a Buy rating and set a $100 target on Oct. 22, 2025. Not all firms agree—Weiss Research rates the stock a Sell, arguing much of the company's growth is already priced in.
| 
